New Phase 1 Clinical Trial Evaluating MMI-0100 in Pulmonary Disorders now Recruiting
Moerae Matrix Inc. recently announced the start of a second Phase 1 clinical trial with MMI-0100, a therapeutic drug developed for pulmonary disorders associated with fibrosis and inflammation, as is the case with idiopathic pulmonary fibrosis (IPF). IPF is a progressive fatal lung disease in which the alveoli and the…